-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $30

Benzinga·09/03/2026 13:23:37
Listen to the news
Barclays analyst Lukas Shumway maintains Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and raises the price target from $17 to $30.